Article
The Antimicrobial efficacy of Elaeis guineensis: characterization, in vitro and in vivo studies.
Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Pulau Pinang 11800, Malaysia.
Molecules (impact factor:
2.39).
01/2012;
17(5):4860-77.
DOI:10.3390/molecules17054860
Source: PubMed
- Citations (35)
-
Cited In (0)
-
Article: Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.
[show abstract] [hide abstract]
ABSTRACT: The Infectious Diseases Society of America (IDSA) continues to view with concern the lean pipeline for novel therapeutics to treat drug-resistant infections, especially those caused by gram-negative pathogens. Infections now occur that are resistant to all current antibacterial options. Although the IDSA is encouraged by the prospect of success for some agents currently in preclinical development, there is an urgent, immediate need for new agents with activity against these panresistant organisms. There is no evidence that this need will be met in the foreseeable future. Furthermore, we remain concerned that the infrastructure for discovering and developing new antibacterials continues to stagnate, thereby risking the future pipeline of antibacterial drugs. The IDSA proposed solutions in its 2004 policy report, "Bad Bugs, No Drugs: As Antibiotic R&D Stagnates, a Public Health Crisis Brews," and recently issued a "Call to Action" to provide an update on the scope of the problem and the proposed solutions. A primary objective of these periodic reports is to encourage a community and legislative response to establish greater financial parity between the antimicrobial development and the development of other drugs. Although recent actions of the Food and Drug Administration and the 110th US Congress present a glimmer of hope, significant uncertainly remains. Now, more than ever, it is essential to create a robust and sustainable antibacterial research and development infrastructure--one that can respond to current antibacterial resistance now and anticipate evolving resistance. This challenge requires that industry, academia, the National Institutes of Health, the Food and Drug Administration, the Centers for Disease Control and Prevention, the US Department of Defense, and the new Biomedical Advanced Research and Development Authority at the Department of Health and Human Services work productively together. This report provides an update on potentially effective antibacterial drugs in the late-stage development pipeline, in the hope of encouraging such collaborative action.Clinical Infectious Diseases 12/2008; 48(1):1-12. · 9.15 Impact Factor -
Article: Anti-infective research and development--problems, challenges, and solutions.
The Lancet Infectious Diseases 02/2007; 7(1):68-78. · 17.39 Impact Factor -
Article: Experience of European intensive care physicians with infections due to antibiotic-resistant bacteria, 2009.
[show abstract] [hide abstract]
ABSTRACT: A survey was performed among European intensive care physicians to obtain information about their perception and experience with selected antibiotic-resistant bacteria. Seventy-eight out of 95 (82%) participants considered having to deal with infections due to antibiotic-resistant bacteria in the intensive care unit where they work was a major or significant problem. Methicillin-resistant Staphylococcus aureus (MRSA) and third-generation cephalosporin-resistant Enterobacteriaceae were the most frequently reported antibiotic-resistant bacteria with 69 (73%) and 67 (71%) participants reporting having treated at least one patient with such an infection during the preceding six months, respectively. Antibiotic-resistant Gram-negative bacteria, including carbapenem-resistant Enterobacteriaceae, were more frequently reported than any selected antibiotic-resistant Gram-positive bacteria, with the exception of MRSA. Fifty (53%) participants declared having treated at least one patient infected with a bacterium totally or almost totally resistant to available antibiotics during the past six months, with 8 participants having treated more than 10 such patients and 13 having treated from 3 to 10 such patients.Euro surveillance: bulletin europeen sur les maladies transmissibles = European communicable disease bulletin 01/2009; 14(45). · 6.15 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
2 times
anticandidal activity
anticandidal agent
Arecaceae
C. albicans
E. guineensis
E. guineensis exhibits excellent antimicrobial activity
Elaeis guineensis Jacq
exhibited good anticandidal activity
extract-treated C. albicans
fungal strains
major alterations
marked inhibitory effect
MIC
multi-drug resistant pathogenic microorganisms
new antimicrobials
optical density
TEM studies
vivo antimicrobial activity
yeast cells